<DOC>
	<DOCNO>NCT01215669</DOCNO>
	<brief_summary>This study design assess immunogenicity safety 2010-2011 NH season formulation intradermal ( ID ) influenza vaccine part post registration commitment . Objectives : - For group , evaluate compliance , term immunogenicity , correspond strength intradermal ( ID ) intramuscular ( IM ) influenza vaccine Northern Hemisphere ( NH ) 2010 2011 formulation requirement Committee Human Medicinal Products ( CHMP ) Note Guidance ( NfG ) CPMP/BWP/214/96 - For group , describe safety</brief_summary>
	<brief_title>Study Sanofi Pasteur 's Intradermal Influenza Vaccine ( IDfluâ„¢ ) Adults Elderly Korea</brief_title>
	<detailed_description>All participant receive single dose study vaccine Day 0 . Immunogenicity data collect vaccination Day 21 post vaccination . Safety assess throughout study .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 18 year day inclusion Informed consent form sign date Able attend schedule visit comply trial procedure For woman childbearing potential , use effective method contraception abstinence least 4 week prior vaccination least 4 week vaccination . Known systemic hypersensitivity egg , chicken protein , neomycin , formaldehyde octoxynol9 , vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Known pregnancy , positive urine pregnancy test Currently breastfeed child History seasonal influenza vaccination within previous 6 month ( pandemic H1N1 influenza vaccine ) Receipt influenza vaccine ( either seasonal pandemic vaccine ) clinical trial within previous 12 month Known suspected congenital acquire immunodeficiency , result example : endstage renal disease require dialysis ; active neoplastic disease active hematologic malignancy ; receipt immunosuppressive therapy immunemodifying drug , limited anticancer chemotherapy radiation therapy within precede 6 month , longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History seropositivity Human Immunodeficiency Virus ( HIV ) , Hepatitis B , Hepatitis C Receipt blood bloodderived product past 3 month , might interfere assessment immune response Chronic illness , opinion investigator , stage might interfere trial conduct completion History thrombocytopenia , contraindicate intramuscular ( IM ) vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate IM vaccination , investigator 's judgment Receipt vaccine 4 week precede trial vaccination Planned receipt vaccine 3 week follow trial vaccination Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination Planned participation another clinical trial present trial period Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Current alcohol abuse drug addiction might interfere ability comply trial procedure Identified employee Investigator study department , direct involvement propose study study direction Investigator study department well family member ( i.e. , immediate , husband , wife child , adopt natural ) employee Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Influenza Virus Vaccines</keyword>
	<keyword>Intradermal Injections</keyword>
</DOC>